JP2016530299A5 - - Google Patents

Download PDF

Info

Publication number
JP2016530299A5
JP2016530299A5 JP2016540401A JP2016540401A JP2016530299A5 JP 2016530299 A5 JP2016530299 A5 JP 2016530299A5 JP 2016540401 A JP2016540401 A JP 2016540401A JP 2016540401 A JP2016540401 A JP 2016540401A JP 2016530299 A5 JP2016530299 A5 JP 2016530299A5
Authority
JP
Japan
Prior art keywords
diazaspiro
decane
amino
pyrimidin
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016540401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530299A (ja
JP6470290B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/054202 external-priority patent/WO2015035113A1/en
Publication of JP2016530299A publication Critical patent/JP2016530299A/ja
Publication of JP2016530299A5 publication Critical patent/JP2016530299A5/ja
Application granted granted Critical
Publication of JP6470290B2 publication Critical patent/JP6470290B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016540401A 2013-09-06 2014-09-05 トリプトファンヒドロキシラーゼ阻害薬としてのスピロ環式化合物 Expired - Fee Related JP6470290B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361874545P 2013-09-06 2013-09-06
US61/874,545 2013-09-06
US201361899943P 2013-11-05 2013-11-05
US61/899,943 2013-11-05
US201462004385P 2014-05-29 2014-05-29
US62/004,385 2014-05-29
PCT/US2014/054202 WO2015035113A1 (en) 2013-09-06 2014-09-05 Spirocyclic compounds as tryptophan hydroxylase inhibitors

Publications (3)

Publication Number Publication Date
JP2016530299A JP2016530299A (ja) 2016-09-29
JP2016530299A5 true JP2016530299A5 (enExample) 2017-10-12
JP6470290B2 JP6470290B2 (ja) 2019-02-13

Family

ID=51743540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540401A Expired - Fee Related JP6470290B2 (ja) 2013-09-06 2014-09-05 トリプトファンヒドロキシラーゼ阻害薬としてのスピロ環式化合物

Country Status (30)

Country Link
US (8) US9199994B2 (enExample)
EP (1) EP3041842B8 (enExample)
JP (1) JP6470290B2 (enExample)
KR (1) KR102336075B1 (enExample)
CN (1) CN105764902B (enExample)
AR (1) AR097571A1 (enExample)
AU (1) AU2014315109B2 (enExample)
CA (1) CA2922933C (enExample)
CL (1) CL2016000509A1 (enExample)
CY (1) CY1122652T1 (enExample)
DK (1) DK3041842T3 (enExample)
EA (1) EA032304B1 (enExample)
EC (1) ECSP16014324A (enExample)
ES (1) ES2780828T3 (enExample)
HR (1) HRP20200098T1 (enExample)
HU (1) HUE047574T2 (enExample)
IL (1) IL244315B (enExample)
LT (1) LT3041842T (enExample)
MX (1) MX371191B (enExample)
MY (1) MY186265A (enExample)
PE (1) PE20160648A1 (enExample)
PH (1) PH12016500416B1 (enExample)
PL (1) PL3041842T3 (enExample)
PT (1) PT3041842T (enExample)
RS (1) RS59871B1 (enExample)
SG (2) SG10201802118QA (enExample)
SI (1) SI3041842T1 (enExample)
TW (1) TWI652267B (enExample)
UA (1) UA119247C2 (enExample)
WO (1) WO2015035113A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119247C2 (uk) * 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN107176940B (zh) * 2016-03-09 2019-05-28 江苏正大丰海制药有限公司 一种替卡法林的制备方法
WO2018060949A1 (en) * 2016-09-30 2018-04-05 Roivant Sciences Gmbh Tryptophan hydroxylase inhibitors for use in the treatment of liver diseases
AR110150A1 (es) * 2016-11-09 2019-02-27 Roivant Sciences Gmbh Procesos para la preparación de inhibidores de tph1
US10472313B1 (en) 2018-02-18 2019-11-12 Graphene 3D Lab Inc. Process for synthesizing trifluoroketones
US11203597B2 (en) * 2018-11-14 2021-12-21 Altavant Sciences Gmbh Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing
AU2019382168A1 (en) * 2018-11-16 2021-06-03 Altavant Sciences Gmbh A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
US20200188399A1 (en) * 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating interstitial lung disease
WO2020128608A1 (en) 2018-12-17 2020-06-25 Altavant Sciences Gmbh Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension
US11607413B2 (en) 2019-01-30 2023-03-21 Altavant Sciences Gmbh Dosage regime and method for treating pulmonary arterial hypertension
CN113784717A (zh) * 2019-03-15 2021-12-10 阿尔塔万特科学公司 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药
EP4069847A4 (en) * 2019-12-02 2023-11-15 Onspira Therapeutics, Inc. Treatment of lower airways disorders
CN111007170B (zh) * 2019-12-13 2021-06-29 中国农业科学院农产品加工研究所 骨肽干预治疗骨质疏松中的生物标志物、筛选方法及用途
CA3165432A1 (en) * 2020-01-31 2021-08-05 Stephen A. Wring Dosages and methods for treating pulmonary arterial hypertension with rodatristat
WO2023062595A1 (en) 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl
WO2023079486A1 (en) 2021-11-03 2023-05-11 Altavant Sciences Gmbh Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan
CN120769851A (zh) * 2023-02-09 2025-10-10 美国杰龙生物医药公司 端粒酶抑制剂化合物
WO2025008449A1 (en) 2023-07-05 2025-01-09 Institut National de la Santé et de la Recherche Médicale Use of tryptophan hydroxylase 1 (tph1) inhibitors for the treatment of atherosclerosis

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1050373A (zh) 1989-05-16 1991-04-03 梅迪斯化学药物工厂普特两合股份公司 制备旋光2-芳基链烷酸,特别是2-芳基丙酸的方法
DK0927183T3 (da) 1996-08-28 2004-11-29 Procter & Gamble Spirocykliske metalloprotease-inhibitorer
HUP0302772A3 (en) 2000-03-07 2007-03-28 Sanofi Aventis Deutschland Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
KR20040068240A (ko) 2001-12-14 2004-07-30 노보 노르디스크 에이/에스 호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용
DE10247680B4 (de) 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase
AU2004247319A1 (en) 2003-06-12 2004-12-23 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
EP1636187A1 (en) 2003-06-12 2006-03-22 Novo Nordisk A/S Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
DE102005002130A1 (de) 2005-01-17 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte N-Aminomethylensulfonamide, ihre Herstellung und Verwendung als Arzneimittel
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
AU2006337137B2 (en) 2005-12-29 2012-06-14 Tersera Therapeutics Llc Multicyclic amino acid derivatives and methods of their use
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
CA2676920A1 (en) * 2007-02-12 2008-08-21 Merck & Co., Inc. Piperidine derivatives
TW200908981A (en) 2007-05-16 2009-03-01 Lilly Co Eli Triazolyl aminopyrimidine compounds
CA2693400A1 (en) 2007-07-11 2009-01-15 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
BRPI0813835A2 (pt) 2007-07-26 2017-06-06 Lexicon Pharmaceuticals Inc métodos de afetar o trânsito gastrointestinal e esvaziamento gástrico, e compostos úteis a esse respeito
US20100255001A1 (en) 2007-09-24 2010-10-07 Universität Zürich Prorektorat Mnw Blockers of serotonin and its receptors for the treatment of hepatitis
BRPI0908719A2 (pt) 2008-03-31 2015-08-18 Univ Columbia Metodos de diagnóstico, prevenção e tratamento de doenças de massa óssea
CN101591332B (zh) 2008-05-30 2014-04-16 莱西肯医药有限公司 基于4-苯基-6-(2,2,2-三氟-1-苯基乙氧基)嘧啶的化合物及其应用方法
CN104045626B (zh) 2008-05-30 2017-01-11 莱西肯医药有限公司 基于4-苯基-6-(2,2,2-三氟-1-苯基乙氧基)嘧啶的化合物及其应用方法
TW201022267A (en) 2008-10-23 2010-06-16 Gruenenthal Gmbh Substituierte pyrimidin-und triazin-derivate
US8614222B2 (en) 2008-11-13 2013-12-24 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating low bone mass diseases
WO2010065333A1 (en) 2008-12-01 2010-06-10 Lexicon Pharmaceuticals, Inc. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis
EP2411380A1 (en) 2009-03-26 2012-02-01 Ranbaxy Laboratories Limited Process for the preparation of desloratadine
TW201103540A (en) 2009-06-16 2011-02-01 Ono Pharmaceutical Co Compound having spiro-linked cyclic group and uses thereof
US8796297B2 (en) * 2009-06-30 2014-08-05 Abbvie Inc. 4-substituted-2-amino-pyrimidine derivatives
US8815883B2 (en) 2009-11-02 2014-08-26 The Trustees Of Columbia Unviersity In The City Of New York Compounds and methods for inhibiting serotonin synthesis
EP2496231A1 (en) 2009-11-05 2012-09-12 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
WO2011063181A1 (en) 2009-11-23 2011-05-26 Lexicon Pharmaceuticals, Inc. Methods and assays for the treatment of irritable bowel syndrome
US20130137635A1 (en) 2010-02-10 2013-05-30 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
WO2011103196A1 (en) * 2010-02-17 2011-08-25 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
SG186989A1 (en) 2010-07-14 2013-02-28 Novartis Ag Ip receptor agonist heterocyclic compounds
MX2013003913A (es) * 2010-10-08 2013-09-26 Abbvie Inc Compuestos de furo [3, 2-d] pirimidina.
TW201245183A (en) 2010-11-05 2012-11-16 Lexicon Pharmaceuticals Inc Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
SG11201401583YA (en) 2011-10-17 2014-09-26 Lexicon Pharmaceuticals Inc Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
WO2013074889A1 (en) 2011-11-17 2013-05-23 The Trustees Of Columbia University In The City Of New York Methods of treating and preventing leukemia and other cancers of the blood and bone
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802585A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
US20140378463A1 (en) 2012-01-13 2014-12-25 Novartis Ag IP receptor agonist heterocyclic compounds
JP6073923B2 (ja) 2012-01-13 2017-02-01 ノバルティス アーゲー 肺動脈高血圧症(pah)および関連障害の治療のためのip受容体アゴニストとしての縮合ピロール
WO2013105061A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802584B1 (en) 2012-01-13 2015-11-18 Novartis AG Salts of an ip receptor agonist
EP2634190A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
WO2013148978A1 (en) 2012-03-30 2013-10-03 Lexicon Pharmaceuticals, Inc. Methods and compositions for the treatment of necrotizing enterocolitis
WO2014082034A1 (en) 2012-11-26 2014-05-30 Lexicon Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome
WO2014124523A1 (en) 2013-02-15 2014-08-21 Mcmaster University A method of treating obesity
WO2014195847A2 (en) 2013-06-03 2014-12-11 Actelion Pharmaceuticals Ltd Novel use of stable isotope labeled l-tryptophan
UA119247C2 (uk) * 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
CN105745211B (zh) 2013-11-19 2017-09-26 埃科特莱茵药品有限公司 作为色氨酸羟化酶的抑制剂的三环咪唑化合物
AR098436A1 (es) 2013-11-19 2016-05-26 Actelion Pharmaceuticals Ltd Compuestos tricíclicos de piperidina
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
EP3061761A1 (en) 2015-02-24 2016-08-31 Max-Delbrück-Centrum für Molekulare Medizin Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
EP3292127A1 (en) 2015-05-04 2018-03-14 Actelion Pharmaceuticals Ltd Tricyclic piperidine compounds

Similar Documents

Publication Publication Date Title
JP2016530299A5 (enExample)
HRP20200098T1 (hr) Spirociklični spojevi kao inhibitori triptofan hidroksilaze
RU2481333C2 (ru) Производные 1,1,1-трифтор-2-гидрокси-3-фенилпропана
US8921357B2 (en) Pyridazinone derivatives
RU2014139601A (ru) Ингибиторы серин/треониновых киназ
CA2710092C (en) Pyridazinone derivatives
CA2747863C (en) Pyridazinone derivatives
US9365562B2 (en) 1,3 substituted azetidine PDE10 inhibitors
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
AU2016314898B2 (en) 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
JP2014531465A5 (enExample)
JP2019523233A5 (enExample)
KR20100045471A (ko) 피리돈 gpr119 g 단백질-커플링된 수용체 효능제
JP2010508338A5 (enExample)
JP2008513514A5 (enExample)
RU2009120882A (ru) Соединения и композиции, как ингибиторы протеинкиназы
CN102295637A (zh) 5-脂氧合酶活化蛋白(flap)抑制剂
CN1409708A (zh) 酪氨酸激酶抑制剂
US20120041024A1 (en) Quinolyl amines as kinase inhibitors
RU2017126199A (ru) Биарильное производное в качестве агониста gpr120
EA032609B1 (ru) Соединения аминопиримидинила в качестве ингибиторов jak
RU2011107437A (ru) Ингибиторы кинуренин-3-моноксигеназы
KR20080066989A (ko) 5-리폭시게나제-활성화 단백질(flap) 억제제
HRP20201469T1 (hr) Derivati tetrahidroizokinolina